share_log

GSK's EAGLE-1 Phase 3 Data Show Potential For Gepotidacin As A New Oral Treatment Option For Uncomplicated Urogenital Gonorrhea

Benzinga ·  Apr 17 05:32
  • Gepotidacin achieved a 92.6% microbiological success rate and was non-inferior to the leading combination treatment
  • EAGLE-1 is the third positive pivotal trial for gepotidacin, a potential first-in-class oral antibiotic as part of GSK's industry-leading infectious diseases portfolio
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment